Present and future pharmacotherapeutic agents in heart failure: An evolving paradigm

British Journal of Pharmacology

Volumn 173, Issue 12, 2016, Pages 1911-1924

  Loudon, Brodie L ^a   Noordali, Hannah ^b   Gollop, Nicholas D ^a   Frenneaux, Michael P ^a   Madhani, Melanie ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARDIAC GLYCOSIDE; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; ENKEPHALINASE INHIBITOR; EPLERENONE; ETOMOXIR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IVABRADINE; LOOP DIURETIC AGENT; METOPROLOL; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; NITRITE; OMAPATRILAT; PERHEXILINE; RAMIPRIL; RANOLAZINE; SACUBITRIL PLUS VALSARTAN; SPIRONOLACTONE; TRIMETAZIDINE; UNINDEXED DRUG; VALSARTAN; CARDIOVASCULAR AGENT;

CARDIAC MUSCLE CELL; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; EVIDENCE BASED MEDICINE; FATTY ACID METABOLISM; GLUCOSE METABOLISM; GLUCOSE OXIDATION; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE METABOLISM; HUMAN; MULTICENTER STUDY (TOPIC); NEW YORK HEART ASSOCIATION CLASS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; METABOLISM;

CARDIOVASCULAR AGENTS; HEART FAILURE; HUMANS; NITRITES; PERHEXILINE;

EID: 84965162741     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13480     Document Type: Review

References (120)

1. Abozguia K, Elliott P, Mckenna W, Phan TT, Nallur-Shivu G, Ahmed I, et al., (2010). Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy. Circulation 122: 1562-1569.
2. AIRE Study Group (1993). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342: 821-828.
3. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 172: 5744-5869.
4. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 172: 5956-5978.
5. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al., (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024-6109.
6. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, et al., (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110-6202.
7. Ashrafian H, Horowitz JD, Frenneaux MP, (2007). Perhexiline. Cardiovasc Drug Rev 25: 76-97.
8. Bailey JC, Feelisch M, Horowitz JD, Frenneaux MP, Madhani M, (2014). Pharmacology and therapeutic role of inorganic nitrite and nitrate in vasodilatation. Pharmacol Ther 144: 303-320.
9. Bailey SJ, Winyard P, Vanhatalo A, Blackwell JR, Dimenna FJ, Wilkerson DP, et al., (2009). Dietary nitrate supplementation reduces the O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans. J Appl Physiol 107: 1144-1155.
10. Basu S, Azarova NA, Font MD, King SB, Hogg N, Gladwin MT, et al., (2008). Nitrite reductase activity of cytochrome c. J Biol Chem 283: 32590-32597.
11. Beadle R, Frenneaux M, (2010). Magnetic resonance spectroscopy in myocardial disease. Expert Rev Cardiovasc Ther 8: 269-277.
12. Braunwald E, Bristow MR, (2000). Congestive heart failure: fifty years of progress. Circulation 102: IV14-IV23.
13. Brown NJ, Vaughan DE, (1998). Angiotensin-converting enzyme inhibitors. Circulation 97: 1411-1420.
14. Burgoyne JR, Mongue-Din H, Eaton P, Shah AM, (2012). Redox signaling in cardiac physiology and pathology. Circ Res 111: 1091-1106.
15. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, et al., (2004). Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291: 309-316.
16. Chatterjee S, Biondi-Zoccai G, Abbate A, D'ascenzo F, Castagno D, Van Tassell B, et al., (2013). Benefits of beta blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ 346: f55.
17. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, (2003). Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107: 3133-3140.
18. CIBIS-II Study Group (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353: 9-13.
19. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, (2006). The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. Eur Heart J 27: 2338-2345.
20. Clerc P, Rigoulet M, Leverve X, Fontaine E, (2007). Nitric oxide increases oxidative phosphorylation efficiency. J Bioenerg Biomembr 39: 158-166.
21. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al., (1986). Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 314: 1547-1552.
22. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al., (1991). A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 325: 303-310.
23. Cohn JN, Tognoni G, (2001). A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345: 1667-1675.
24. CONSENSUS Trial Study Group (1987). Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435.
25. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK, (1991). Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 338: 973-976.
26. Cook CA, (1988). Pathophysiologic and pharmacotherapy considerations in the management of the black hypertensive patient. Am Heart J 116: 288-295.
27. Dai DF, Hsieh EJ, Chen T, Menendez LG, Basisty NB, Tsai L, et al., (2013). Global proteomics and pathway analysis of pressure-overload-induced heart failure and its attenuation by mitochondrial-targeted peptides. Circ Heart Fail 6: 1067-1076.
28. Digitalis Investigation Group (1997). The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525-533.
29. Doenst T, Nguyen TD, Abel ED, (2013). Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res 113: 709-724.
30. Dzau VJ, Hirsch AT, (1990). Emerging role of the tissue renin-angiotensin systems in congestive heart failure. Eur Heart J 11 (Suppl B): 65-71.
31. Dzau VJ, Re R, (1994). Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 89: 493-498.
32. Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A, (2002). Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 82: 149-158.
33. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al., (2005). Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 26: 215-225.
34. Follath F, Cleland JG, Klein W, Murphy R, (1998). Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 32: 1167-1172.
35. Foster MW, Mcmahon TJ, Stamler JS, (2003). S-nitrosylation in health and disease. Trends Mol Med 9: 160-168.
36. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R, (2014). Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 371: 1091-1099.
37. Fox K, Ford I, Steg PG, Tendera M, Ferrari R, (2008). Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 372: 807-816.
38. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M, et al., (2006). A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 48: 992-998.
39. Furberg CD, Yusuf S, (1985). Effect of vasodilators on survival in chronic congestive heart failure. Am J Cardiol 55: 1110-1113.
40. Gheorghiade M, Greene SJ, Butler J, Filippatos G, Lam CS, Maggioni AP, et al., (2015). Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. JAMA 314: 2251-2262.
41. Gladwin MT, Kim-Shapiro DB, (2008). The functional nitrite reductase activity of the heme-globins. Blood 112: 2636-2647.
42. Goffart S, Von Kleist-Retzow JC, Wiesner RJ, (2004). Regulation of mitochondrial proliferation in the heart: power-plant failure contributes to cardiac failure in hypertrophy. Cardiovasc Res 64: 198-207.
43. Granger CB, Mcmurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al., (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362: 772-776.
44. Greenberg BH, Chou W, Saikali KG, Escandon R, Lee JH, Chen MM, et al., (2015). Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail 3: 22-29.
45. Guazzi M, (2008). Clinical use of phosphodiesterase-5 inhibitors in chronic heart failure. Circ Heart Fail 1: 272-280.
46. Guazzi M, Samaja M, Arena R, Vicenzi M, Guazzi MD, (2007). Long-term use of sildenafil in the therapeutic management of heart failure. J Am Coll Cardiol 50: 2136-2144.
47. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al., (2009). Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 11: 119-129.
48. Hobbs FD, Roalfe AK, Davis RC, Davies MK, Hare R, (2007). Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). Eur Heart J 28: 1128-1134.
49. Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, et al., (2007). A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 113: 205-212.
50. Horowitz JD, Chirkov YY, (2010). Perhexiline and hypertrophic cardiomyopathy: a new horizon for metabolic modulation. Circulation 122: 1547-1549.
51. Horowitz JD, Sia ST, Macdonald PS, Goble AJ, Louis WJ, (1986). Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol 13: 219-229.
52. Kantor PF, Lucien A, Kozak R, Lopaschuk GD, (2000). The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 86: 580-588.
53. Kapil V, Weitzberg E, Lundberg JO, Ahluwalia A, (2014). Clinical evidence demonstrating the utility of inorganic nitrate in cardiovascular health. Nitric Oxide 38: 45-57.
54. Kato T, Niizuma S, Inuzuka Y, Kawashima T, Okuda J, Tamaki Y, et al., (2010). Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 3: 420-430.
55. Kennedy JA, Horowitz JD, (1998). Effect of trimetazidine on carnitine palmitoyltransferase-1 in the rat heart. Cardiovasc Drugs Ther 12: 359-363.
56. Kennedy JA, Unger SA, Horowitz JD, (1996). Inhibition of carnitine palmitoyltransferase-1 in rat heart and liver by perhexiline and amiodarone. Biochem Pharmacol 52: 273-280.
57. Kostis JB, Packer M, Black HR, Schmieder R, Henry D, Levy E, (2004). Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 17: 103-111.
58. Larsen FJ, Schiffer TA, Borniquel S, Sahlin K, Ekblom B, Lundberg JO, et al., (2011). Dietary inorganic nitrate improves mitochondrial efficiency in humans. Cell Metab 13: 149-159.
59. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L, et al., (2005). Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 112: 3280-3288.
60. Lopaschuk GD, Rebeyka IM, Allard MF, (2002). Metabolic modulation: a means to mend a broken heart. Circulation 105: 140-142.
61. Luiken JJ, Niessen HE, Coort SL, Hoebers N, Coumans WA, Schwenk RW, et al., (2009). Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J 419: 447-455.
62. Lundberg JO, Weitzberg E, Gladwin MT, (2008). The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 7: 156-167.
63. Maher AR, Milsom AB, Gunaruwan P, Abozguia K, Ahmed I, Weaver RA, et al., (2008). Hypoxic modulation of exogenous nitrite-induced vasodilation in humans. Circulation 117: 670-677.
64. Maier LS, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al., (2013). RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail 1: 115-122.
65. Mancini D, Colombo PC, (2015). Left ventricular assist devices: a rapidly evolving alternative to transplant. J Am Coll Cardiol 65: 2542-2555.
66. Mann DL, Kent RL, Parsons B, Cooper GT, (1992). Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85: 790-804.
67. Mann DL, Mcmurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al., (2004). Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109: 1594-1602.
68. Massie BM, Carson PE, Mcmurray JJ, Komajda M, Mckelvie R, Zile MR, et al., (2008). Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359: 2456-2467.
69. Mccormack JG, Barr RL, Wolff AA, Lopaschuk GD, (1996). Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93: 135-142.
70. Mcdowell G, Nicholls DP, (1999). The endopeptidase inhibitor, candoxatril, and its therapeutic potential in the treatment of chronic cardiac failure in man. Expert Opin Investig Drugs 8: 79-84.
71. Mcmurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al., (2012). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33: 1787-1847.
72. Mcmurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al., (2003). Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362: 767-771.
73. Merit-Hf Study Group (1999). Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007.
74. Munzel T, Daiber A, Mulsch A, (2005). Explaining the phenomenon of nitrate tolerance. Circ Res 97: 618-628.
75. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, et al., (1996). Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest 98: 1465-1470.
76. Neglia D, De Caterina A, Marraccini P, Natali A, Ciardetti M, Vecoli C, et al., (2007). Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 293: H3270-H3278.
77. Neubauer S, (2007). The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151.
78. Ormerod JO, Arif S, Mukadam M, Evans JD, Beadle R, Fernandez BO, et al., (2015). Short-term intravenous sodium nitrite infusion improves cardiac and pulmonary hemodynamics in heart failure patients. Circ Heart Fail 8: 565-571.
79. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al., (2002). Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106: 2194-2199.
80. Packer M, Mcmurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al., (2015). Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 131: 54-61.
81. Paul M, Poyan Mehr A, Kreutz R, (2006). Physiology of local renin-angiotensin systems. Physiol Rev 86: 747-803.
82. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., (2014). The IUPHAR/BPS guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42: D1098-D1106.
83. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, et al., (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 327: 669-677.
84. Pfeffer MA, Mcmurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al., (2003). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349: 1893-1906.
85. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al., (2014). Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370: 1383-1392.
86. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al., (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341: 709-717.
87. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM, (2003). Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289: 871-878.
88. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, et al., (2000). Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102: 3060-3067.
89. Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al., (2015). Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med 373: 2314-2324.
90. Rona G, (1985). Catecholamine cardiotoxicity. J Mol Cell Cardiol 17: 291-306.
91. Sack MN, Rader TA, Park S, Bastin J, Mccune SA, Kelly DP, (1996). Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94: 2837-2842.
92. Sarraf M, Masoumi A, Schrier RW, (2009). Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 4: 2013-2026.
93. Schmidt-Schweda S, Holubarsch C, (2000). First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 99: 27-35.
94. Schrauwen P, Hesselink MK, (2004). The role of uncoupling protein 3 in fatty acid metabolism: protection against lipotoxicity? Proc Nutr Soc 63: 287-292.
95. Schwarz K, Siddiqi N, Singh S, Neil CJ, Dawson DK, Frenneaux MP, (2014). The breathing heart-mitochondrial respiratory chain dysfunction in cardiac disease. Int J Cardiol 171: 134-143.
96. Shah AM, Mann DL, (2011). In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet 378: 704-712.
97. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JD, (1982). Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. Br Med J (Clin Res Ed) 284: 295-299.
98. Siddiqi N, Singh S, Beadle R, Dawson D, Frenneaux M, (2013). Cardiac metabolism in hypertrophy and heart failure: implications for therapy. Heart Fail Rev 18: 595-606.
99. Singh S, Schwarz K, Horowitz J, Frenneaux M, (2014). Cardiac energetic impairment in heart disease and the potential role of metabolic modulators: a review for clinicians. Circ Cardiovasc Genet 7: 720-728.
100. SOLVD Investigators (1992). Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691.
101. Stanley WC, Recchia FA, Lopaschuk GD, (2005). Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129.
102. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al., (2010). Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376: 875-885.
103. Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al., (2001). Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 22: 2267-2274.
104. Taylor AL, Ziesche S, Yancy C, Carson P, D'agostino R Jr, Ferdinand K, et al., (2004). Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 351: 2049-2057.
105. Teerlink JR, (2010). Ivabradine in heart failure-no paradigm SHIFT...yet. Lancet 376: 847-849.
106. Tilemann L, Ishikawa K, Weber T, Hajjar RJ, (2012). Gene therapy for heart failure. Circ Res 110: 777-793.
107. Torre-Amione G, Anker SD, Bourge RC, Colucci WS, Greenberg BH, Hildebrandt P, et al., (2008). Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet 371: 228-236.
108. Totzeck M, Hendgen-Cotta UB, Luedike P, Berenbrink M, Klare JP, Steinhoff HJ, et al., (2012). Nitrite regulates hypoxic vasodilation via myoglobin-dependent nitric oxide generation. Circulation 126: 325-334.
109. Turcani M, Rupp H, (1997). Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 96: 3681-3686.
110. Unger SA, Robinson MA, Horowitz JD, (1997). Perhexiline improves symptomatic status in elderly patients with severe aortic stenosis. Aust N Z J Med 27: 24-28.
111. Van Der Vusse GJ, Van Bilsen M, Glatz JF, (2000). Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 45: 279-293.
112. Van Faassen EE, Bahrami S, Feelisch M, Hogg N, Kelm M, Kim-Shapiro DB, et al., (2009). Nitrite as regulator of hypoxic signaling in mammalian physiology. Med Res Rev 29: 683-741.
113. Vardeny O, Miller R, Solomon SD, (2014). Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. JACC Heart Fail 2: 663-670.
114. Webb AJ, Milsom AB, Rathod KS, Chu WL, Qureshi S, Lovell MJ, et al., (2008). Mechanisms underlying erythrocyte and endothelial nitrite reduction to nitric oxide in hypoxia: role for xanthine oxidoreductase and endothelial nitric oxide synthase. Circ Res 103: 957-964.
115. Yin X, Dwyer J, Langley SR, Mayr U, Xing Q, Drozdov I, et al., (2013). Effects of perhexiline-induced fuel switch on the cardiac proteome and metabolome. J Mol Cell Cardiol 55: 27-30.
116. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, Mcmurray JJ, et al., (2003). Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-preserved trial. Lancet 362: 777-781.
117. Zamani P, Rawat D, Shiva-Kumar P, Geraci S, Bhuva R, Konda P, et al., (2015). Effect of inorganic nitrate on exercise capacity in heart failure with preserved ejection fraction. Circulation 131: 371-380; discussion 380.
118. Zannad F, Alla F, Dousset B, Perez A, Pitt B, (2000). Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investig Circ 102: 2700-2706.
119. Zannad F, Mcmurray JJ, Krum H, Van Veldhuisen DJ, Swedberg K, Shi H, et al., (2011). Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364: 11-21.
120. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, et al., (2012). Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 59: 913-922.